Oncology

Osimertinib was previously approved as a monotherapy, the first-in-line global standard of care, for non–small cell lung cancer indications.

The pharmacist’s role may vary across different practices and institutions.

This marks the first and only time that an individualized T cell therapy has been approved by the FDA for a solid tumor cancer.

Tigilanol tiglate is a novel, small molecule drug for the intratumoral treatment of solid tumors, inducing tumor cell death and stimulating immune response.

Tucatinib significantly improved median PFS in the overall population and those with brain metastases.

The complexity of the disease and number of treatment options can necessitate a personalized approach.

The investigators note that patients with newly diagnosed multiple melanoma who receive quadruplet treatment have unmet needs that must be further examined in future research.

Since the first FDA biosimilar approval of filgrastim-sndz (Zarxio) in 2015, a total of 44 biosimilars for 15 originator products have been approved and more than 20 are marketed.

The oral therapy is available through a REMS program.

This frequency can allow for faster observation of toxicities and adherence issues.

The approval of irinotecan liposome offers an improved first-line treatment option for individuals diagnosed with metastatic pancreatic adenocarcinoma.

This review summarizes current utilization of anti-HER2 targeted therapy across several non-breast solid tumors in the setting of advanced disease.

Repotrectinib led to a durable anti-tumor response in patients with NTRK-positive locally advanced or metastatic solid tumors.

These disorders can be fatal, making pharmacists’ role in detection crucial.

Progression-free survival in the ixazomib/pegylated liposomal doxorubicin/dexamethasone group was shorter than in the ixazomib/lenalidomide/dexamethasone group.

The results indicate promising rates of complete response, manageable adverse events, and dose-dependent exposure in both dose groups.

Treatment options are distinct in their mechanisms, safety profiles, and implications for patients’ quality of life.

In addition to improved progression-free survival, patients treated with this regimen also showed improved complete response or stronger and were minimal residual disease-negative.

This issue of Pharmacy Practice in Focus: Oncology features the publication's first manuscript to undergo peer review.

"Pharmacy Practice in Focus: Oncology" welcomes the launch of the peer-review process.

Patients readily accepted physical interventions and referrals to oncology clinical pharmacy practitioners.

In addition to managing adverse effects and educating both patients and providers, pharmacists help patients get access to much-needed treatments.

Bevacizumab is a recombinant humanized G1 monoclonal anti-vascular endothelial growth factor antibody that is used in combination with chemotherapy to treat solid tumors.

The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 8, 2024.

Treatment decisions should depend on the patient, their disease, and their disease progression.

In November 2023, the FDA announced an investigation of CAR T-cell therapy based on several reported secondary T-cell malignancies.

Approximately 41% of enrolled patients responded to NX-2127, and the BTK degrader overcame resistance to nearly all BTK mutations that were identified to cause resistance.

According to the authors, the test has promise in guiding treatment but needs further refining to obtain information beyond molecular subtyping.

The findings suggest that greater adherence to the WCRF/AICR Cancer Prevention Recommendations could greatly reduce the risk of all cancers combined, along with 14 others.

Survival rates were similar between non-Hispanic African American and non-Hispanic White patients who received treatment, indicating a need to address barriers to multiple myeloma treatment and racial disparities.